How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions

• Earlier in August 2026, COMPASS Pathways plc announced it is working with the U.S. Department of Veterans Affairs on PIVOT, a multi-site randomized controlled trial testing its COMP360 psilocybin in veterans with treatment-resistant depression, including those with concurrent PTSD, while also presenting at Stifel’s 2026 Biotech Summer Summit in Newport, Rhode Island.
• The VA collaboration highlights federal interest in evaluating COMP360 within a large veteran population, potentially broadening clinical evidence for psilocybin-assisted therapy in complex mental health conditions.
• We’ll now examine how partnering with the VA on the PIVOT trial may influence COMPASS Pathways’ investment narrative and long-term outlook.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

COMPASS Pathways Investment Narrative Recap

To own COMPASS Pathways, you have to believe COMP360 can translate late stage trial data into regulatory approval and real world adoption in treatment resistant depression, while the company manages heavy losses and potential dilution. The new VA PIVOT trial looks additive for the long term evidence base, but it does not change that the key near term catalyst remains the COMP360 NDA process, and the biggest current risk is execution missteps or delays that shorten the cash runway.

In that context, the recent Phase 3 COMP006 Part B data, showing longer term outcomes that support a rolling NDA submission for COMP360 in TRD, looks more directly tied to the main catalyst than the VA collaboration. The PIVOT trial may complement these pivotal data by extending evidence into a complex veteran population with concurrent PTSD, but investors still need to focus on how quickly COMPASS can convert the Phase 3 program into a complete NDA filing and eventual review.

Yet behind the promise of VA collaboration and Phase 3 progress, there is a financing and dilution risk that investors should be aware of...

Read the full narrative on COMPASS Pathways (it's free!)

COMPASS Pathways' narrative projects $284.9 million revenue and $53.9 million earnings by 2029. This implies an earnings increase of about $246 million from -$192.4 million today.

Uncover how COMPASS Pathways' forecasts yield a $24.47 fair value, a 75% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were expecting only about US$72.0 million of revenue and US$12.9 million of earnings by 2029, and they worry that slow real world adoption at interventional psychiatry sites could restrain volumes even if trials succeed, so as you weigh the VA PIVOT news, it is worth remembering how far apart views can be and exploring a range of possible outcomes before you decide what you believe.

Explore 4 other fair value estimates on COMPASS Pathways - why the stock might be worth just $23.75!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your COMPASS Pathways research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free COMPASS Pathways research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate COMPASS Pathways' overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com